gefitinib has been researched along with Chordoma in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ | 1 |
Adkins, J; Byron, S; Cuyugan, L; Dardis, C; Enriquez, D; Helland, A; Liang, WS; Little, AS; Sekar, S | 1 |
Amary, F; Barnard, M; Brüderlein, S; Cottone, L; Drewry, DH; Flanagan, AM; Guppy, N; Jorgensen, M; Leite, AP; Leithner, A; Möller, P; Pillay, N; Scheipl, S; Smith, JA; Strauss, SJ; Tirabosco, R; Turlais, F; Ye, H; Zuercher, WJ | 1 |
Kjellén, E; Lindén, O; Stenberg, L | 1 |
Debus, J; Hof, H; Welzel, T | 1 |
5 other study(ies) available for gefitinib and Chordoma
Article | Year |
---|---|
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2019 |
Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses.
Topics: Adult; Aged; Ataxia Telangiectasia Mutated Proteins; Checkpoint Kinase 2; Chordoma; Cyclin-Dependent Kinase 4; DNA-Binding Proteins; Female; Gefitinib; Gene Expression Profiling; Genomics; Humans; Male; Middle Aged; Mutation; Nuclear Proteins; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-3; Receptor, Fibroblast Growth Factor, Type 1; Skull Base Neoplasms; Transcription Factors; Transcriptome | 2018 |
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chordoma; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cervical Vertebrae; Cetuximab; Chordoma; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Spinal Cord Compression | 2009 |
Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chordoma; Gefitinib; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Sacrum; Spinal Neoplasms; Treatment Outcome | 2006 |